CareDx Shows Global Leadership at The Transplantation Society’s 29th International Congress | Company

BRISBANE, Calif.–(BUSINESS WIRE)–Sept. 12, 2022–

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ is focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today its prominent participation in the 29th International Congress of The Transplantation Society (TTS 2022) will take place September 10-14 in Buenos Aires, Argentina.

Transplant physicians will present data from over 25 abstracts demonstrating the value of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and AlloSeq cDNA in clinical practice, as well as emerging trends and innovation in transplantation, including artificial intelligence and the potential use of CareDx Molecular Testing Services for monitoring xenotransplantation.

“As a leader in transplantation innovation, CareDx is excited to expand its global presence with data from over 25 abstracts presented at this internationally acclaimed TTS Congress,” said Reg Seeto. , CEO and President of CareDx. “We also look forward to sharing information on the next wave of innovation focused on the latest AiKidney™ and AiCAV™ developments.”

Dr Alexandre Loupy, Paris Transplant Group, added: “I look forward to attending the meeting and discussing how artificial intelligence is transforming patient care by helping doctors adapt plans based on the patient’s risk profile for rejection and post-transplant complications.

About CareDx – The Transplant Society

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions. for transplant patients and caregivers. CareDx offers testing services, products and digital healthcare solutions throughout the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-looking statements

This press release contains forward-looking statements relating to CareDx, Inc., including statements regarding the benefits and potential results that may be achieved through CareDx’s prominent participation in the 29th International Congress of the Transplantation Society (the “ TTS Congress”). These forward-looking statements are based on information currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. , including the risks that CareDx does not realize the expected benefits of its participation in the TTS Congress; the risks that the TTS Congress will not take place at the time and place indicated in this press release; the risks that the data presented at the TTS Congress will not match the statements contained in this press release; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the annual report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the report quarterly report on Form 10-Q for the quarter ended March 31, 2022 filed by CareDx with the SEC on May 5, 2022, the quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed by CareDx with the SEC on August 4, 2022 and other reports that CareDx has filed with the SEC. Each of these items could cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertakes to update or revise these forward-looking statements.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220912005357/en/

CONTACT: CareDx. Inc.

Media Relations

Anna Czene

(818)731-2203

[email protected] Relations

Ian Coney

(415) 722-4563

[email protected]

KEYWORD: CALIFORNIA BRAZIL SOUTH AMERICA LATIN AMERICA NORTH AMERICA EUROPE ARGENTINA UNITED STATES COLOMBIA

KEYWORD INDUSTRY: HEALTH SURGERY GENETIC HEALTH TECHNOLOGY GENERAL HEALTH PHARMACEUTICALS BIOTECHNOLOGY

SOURCE: CareDx, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 09/12/2022 07:01 / DISK: 09/12/2022 07:03

http://www.businesswire.com/news/home/20220912005357/en

Copyright BusinessWire 2022.


Source link

Comments are closed.